Recombinant Human CHFR Protein, N-His from ProteoGenix; catalogue ARO-P10706; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant human CHFR protein is a type of recombinant protein that is produced through genetic engineering techniques. It is a member of the CHFR family of proteins, which are involved in regulating cell division and preventing the development of cancer.
The CHFR gene is located on chromosome 12 in humans and codes for a protein that is 735 amino acids long. The recombinant human CHFR protein is made up of the same amino acid sequence as the native protein, but it is produced in a laboratory setting using recombinant DNA technology.
The structure of recombinant human CHFR protein is similar to that of other proteins in the CHFR family. It contains a conserved N-terminal forkhead-associated (FHA) domain, a central RING finger domain, and a C-terminal forkhead (FKH) domain. These domains are essential for the protein’s function in regulating cell division and preventing cancer development.
The primary activity of recombinant human CHFR protein is to act as a tumor suppressor. It regulates the cell cycle by inhibiting the activity of the anaphase-promoting complex/cyclosome (APC/C), a protein complex that is involved in cell division. This inhibition prevents the premature separation of sister chromatids during cell division, which can lead to chromosomal instability and the development of cancer.
In addition to its role in regulating the cell cycle, recombinant human CHFR protein also plays a role in DNA damage response. It is activated in response to DNA damage and helps to repair damaged DNA. This activity is crucial for maintaining genomic stability and preventing the development of cancer.
Recombinant human CHFR protein has several potential applications in the field of cancer research and treatment. Its ability to regulate the cell cycle and prevent the development of cancer makes it a promising target for cancer therapy.
One potential application is in the development of CHFR-based cancer therapies. By targeting the activity of CHFR, these therapies could potentially prevent the growth and spread of cancer cells.
Recombinant human CHFR protein could also be used as a diagnostic tool for cancer. Since it is activated in response to DNA damage, its levels may be elevated in individuals with certain types of cancer. Measuring the levels of CHFR in a patient’s blood or tissue sample could help to diagnose cancer at an early stage.
Furthermore, recombinant human CHFR protein could be used in drug discovery and development. By studying its structure and activity, researchers could identify potential compounds that can modulate its function and potentially be used as cancer treatments.
In conclusion, recombinant human CHFR protein is a valuable tool in cancer research and has the potential to be developed into new therapies for the treatment of cancer. Its unique structure and activity make it a promising target for further study and application in the fight against cancer.
ProteoGenix catalogue number ARO-P10706. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 15.16 kDa; Fragment: Gln14-Lys126; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
